Pharma-Bio Serv (PBSV) Receivables (2010 - 2026)

Pharma-Bio Serv's Receivables history runs 17 years deep, the most recent figure standing at $2.7 million for Q2 2026.

• Receivables for Q2 2026 came in at $2.7 million, down 48.62% year-over-year; the trailing twelve-month figure through Apr 2026 was $2.7 million (down 48.62% YoY), and the FY2025 annual result was $5.3 million, up 111.08% from the prior year.
• Receivables came in at $2.7 million for Q2 2026 at Pharma-Bio Serv, up from $2.7 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $5.5 million in Q2 2022 to a low of $2.0 million in Q3 2025.
• A 5-year average of $4.0 million and a median of $4.5 million in 2023 frame the typical range for Receivables.
• The largest YoY upside for Receivables was 120.14% in 2025 against a maximum downside of 61.97% in 2025.
• Over 5 years, Receivables stood at $5.0 million in 2022, then decreased by 20.91% to $3.9 million in 2023, then sank by 36.29% to $2.5 million in 2024, then decreased by 5.98% to $2.4 million in 2025, then grew by 15.37% to $2.7 million in 2026.
• The last three Receivables figures came in at $2.7 million (Q2 2026), $2.7 million (Q1 2026), and $2.4 million (Q4 2025), per Business Quant data.